학술논문
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
Document Type
Article
Author
Source
In eClinicalMedicine December 2022 54
Subject
Language
ISSN
2589-5370